Vascular Biogenics Ltd. (VBLT) Receives Consensus Rating of “Buy” from Analysts
Vascular Biogenics Ltd. (NASDAQ:VBLT) has earned an average rating of “Buy” from the six analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $14.75.
A number of brokerages have weighed in on VBLT. HC Wainwright set a $11.00 price target on Vascular Biogenics and gave the stock a “buy” rating in a report on Tuesday, August 15th. Zacks Investment Research downgraded Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. Finally, ValuEngine upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Thursday, August 17th.
Vascular Biogenics (VBLT) traded up 1.00% on Tuesday, reaching $5.05. The company’s stock had a trading volume of 71,767 shares. Vascular Biogenics has a 52-week low of $3.90 and a 52-week high of $6.70. The firm’s 50-day moving average price is $4.37 and its 200-day moving average price is $5.22. The stock’s market cap is $136.40 million.
Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.01. On average, equities analysts expect that Vascular Biogenics will post ($0.82) earnings per share for the current year.
An institutional investor recently bought a new position in Vascular Biogenics stock. KCG Holdings Inc. purchased a new stake in shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 45,106 shares of the biopharmaceutical company’s stock, valued at approximately $248,000. KCG Holdings Inc. owned 0.17% of Vascular Biogenics as of its most recent SEC filing. Institutional investors own 12.99% of the company’s stock.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.